| Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease. | |
| | |
MedLine Citation:
|
PMID: 18928444 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Tumour necrosis factor inhibitors have revolutionised the management of Crohn's disease, but reports of a possible association between concomitant infliximab and immunomodulator therapy and hepatosplenic T-cell lymphoma (a rare form of aggressive non-Hodgkin's lymphoma) have emerged. We describe the first case in Australia of hepatosplenic T-cell lymphoma in a patient who had been treated with infliximab and immunomodulators for Crohn's disease. |
| | |
Authors:
|
Musa Drini; Peter J Prichard; Gregor J E Brown; Finlay A Macrae |
Related Documents
:
|
12840124 - Hospital admissions for human t-cell lymphotropic virus type-1 (htlv-1) associated dise... 7042874 - Glomerular immune complex formation and induction of lymphoma in athymic nude mice by t... 11465724 - Orbital mucosa-associated lymphoid tissue (malt)-type lymphoma in a patient with relaps... 1775404 - Angiofollicular lymph node transformation in hodgkin's lymphoma. 18185134 - Autofluorescence from the outer retina and subretinal space: hypothesis and review. 2630354 - The flash stimulated vep in the diagnosis of glaucoma. |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: The Medical journal of Australia Volume: 189 ISSN: 0025-729X ISO Abbreviation: Med. J. Aust. Publication Date: 2008 Oct |
Date Detail:
|
Created Date: 2008-10-20 Completed Date: 2008-12-17 Revised Date: 2009-04-22 |
Medline Journal Info:
|
Nlm Unique ID: 0400714 Medline TA: Med J Aust Country: Australia |
Other Details:
|
Languages: eng Pagination: 464-5 Citation Subset: IM |
Affiliation:
|
Department of Colorectal Medicine and Genetics, Royal Melbourne Hospital, Melbourne, Victoria, Australia. Musa.Drini@mh.org.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antibodies, Monoclonal / adverse effects*, therapeutic use Crohn Disease / drug therapy Fatal Outcome Humans Immunologic Factors / adverse effects, therapeutic use Liver Neoplasms / chemically induced* Lymphoma, T-Cell / chemically induced* Male Splenic Neoplasms / chemically induced* Tumor Necrosis Factor-alpha / antagonists & inhibitors* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Immunologic Factors; 0/Tumor Necrosis Factor-alpha; 0/infliximab |
| Comments/Corrections | |
Comment In:
|
Med J Aust. 2009 Mar 16;190(6):341-2
[PMID:
19296822
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Impeding the supply of expertise in Australian health care: actions of the Australian and New Zealan...
Next Document: Characterization of SCaMC-3-like/slc25a41, a novel calcium-independent mitochondrial ATP-Mg/Pi carri...